Kidney transplant patients may benefit from common diabetes drugs

This study tested whether two diabetes medications, metformin and empagliflozin, can safely improve metabolic problems (like fat distribution and blood sugar) in people who received a kidney transplant. 105 adult kidney transplant recipients with good kidney function were randomly assigned to one of three groups: metformin, empagliflozin, or standard care. The main goal was to see if these drugs could reduce the ratio of visceral to subcutaneous fat, a marker of metabolic risk, over 12 months.